HCW Biologics Inc.
For the period ended Mar 31, 2026. Filed May 14, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 14, 2026
HCWB$0.95-6.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of cash flows
Condensed Statements of Cash Flows
| Three Months Ended March 31, | ||
|---|---|---|
| 2025 | 2026 | |
| Cash flows from operating activities: | ||
| Net income (loss) | $(2,196,875) | $3,472,480 |
| Adjustments to reconcile net income (loss) to net cash used in operating activities: | ||
| Depreciation and amortization | 419,010 | 142,049 |
| Stock-based compensation | 275,642 | 10,019 |
| Change in fair value of warrant liability | — | (667,343) |
| Noncash revenue from licensing agreement | — | (3,500,000) |
| Commitment fee | 150,000 | — |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | 494,708 | (42,669) |
| Prepaid expenses and other assets | (257,894) | (117,883) |
| Deferred revenue | — | 470,000 |
| Accounts payable and other liabilities | (2,398,447) | (1,341,879) |
| Net cash used in operating activities | (3,513,856) | (1,575,226) |
| Cash flows from investing activities: | ||
| Net cash provided by (used in) investing activities | — | — |
| Cash flows from financing activities: | ||
| Proceeds from issuance of Common Stock | 1,654 | — |
| Proceeds from the issuance and exercise of pre-funded warrants | — | 1,500,000 |
| Issuance costs of pre-funded warrants and Common Stock warrants | — | (389,056) |
| Issuance costs for Common Stock | (22,297) | — |
| Debt repayment | (32,460) | (259,303) |
| Net cash provided by (used in) financing activities | (53,103) | 851,641 |
| Net decrease in cash and cash equivalents | (3,566,959) | (723,585) |
| Cash and cash equivalents at the beginning of the period | 4,674,572 | 1,952,464 |
| Cash and cash equivalents at the end of the period | $1,107,613 | $1,228,879 |
| Supplemental disclosure of cash flow information: | ||
| Cash paid for interest | $244,269 | $171,404 |
| Noncash financing and investing activities: | ||
| Equity dividend to investor | $— | $1,488,472 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.